CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CYTO

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/28	23 : 31	GlobeNewswire Inc.	Altamira Therapeutics Provides Business Update	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/05/23	21 : 47	GlobeNewswire Inc.	Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/05/17	05 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/05/01	21 : 47	GlobeNewswire Inc.	Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/04/24	21 : 47	GlobeNewswire Inc.	Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/04/10	21 : 00	GlobeNewswire Inc.	Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/04/04	21 : 45	GlobeNewswire Inc.	Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/03/25	21 : 47	GlobeNewswire Inc.	Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/02/07	22 : 47	GlobeNewswire Inc.	Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/24	22 : 47	GlobeNewswire Inc.	Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/23	07 : 02	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/22	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/20	06 : 45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/20	06 : 40	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/20	06 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/09	07 : 02	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:CYTO	Altamira Therapeutics Ltd
2024/01/08	22 : 47	GlobeNewswire Inc.	Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/29	22 : 47	GlobeNewswire Inc.	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/11	22 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/11	22 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/11	22 : 00	GlobeNewswire Inc.	Altamira Therapeutics Provides Investor and Business Update	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/08	23 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/12/06	02 : 54	GlobeNewswire Inc.	Altamira Therapeutics to Host Investor & Business Update Call on December 11th	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/30	00 : 20	GlobeNewswire Inc.	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/23	06 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/21	22 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/17	23 : 04	GlobeNewswire Inc.	Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/10	22 : 47	GlobeNewswire Inc.	Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/11/01	05 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd
2023/10/04	22 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CYTO	Altamira Therapeutics Ltd